DOCSLIB.ORG

Official Records

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

E/CONF.58/7 United Nations Conference for the adoption of a Protocol on Psychotropic Substances Vienna — 11 January -19 February 1971 Official Records Volume I • Organizational documents Texts of the revised draft Protocol and of the Convention Record of the work of the Conference Final Act Convention on Psychotropic Substances and Schedules Resolutions UNITED NATIONS United Nations Conference for the adoption of a Protocol on Psychotropic Substances Vienna -—11 January - 19 February 1971 Official Records Volume L* Organizational documents Texts of the revised draft Protocol and of the Convention Record of the work of the Conference Final Act Convention on Psychotropic Substances and Schedules Resolutions UNITED NATIONS - NEW YORK, 1973 INTRODUCTORY NOTE The Official Records of the United Nations Conference for the adoption of a Protocol on Psychotropic Substances are published in two volumes. Volume I (E/CONF.58/7) contains the preliminary (organizational) and the concluding (Final Act, resolutions, etc.) documents of the Conference, the texts of the revised draft Protocol on Psychotropic Substances and the 1971 Convention on Psychotropic Substances, and a record of the work of the Conference leading up to the adoption of the Convention, set out article by article. The volume also contains a complete list of the documents of the Conference. Volume II (E/Conf.58/7/Add.l) contains the summary records of the plenary meetings of the Conference and the minutes of the meetings of the General Com• mittee and the Committee on Control Measures, incorporating the corrections requested by delegations and any other editorial changes. * * * In the present publication, references to "China" and to the "representative(s) of China" are to be understood in the light of General Assembly resolution 2758 (XXVI) of 25 October 1971. By that resolution, the General Assembly inter alia decided: "to restore all its rights to the People's Republic of China and to recognize the representatives of its Government as the only legitimate representatives of China to the United Nations, and to expel forthwith the representatives of Chiang Kai-shek from the place which they unlawfully occupy at the United Nations and in all the organizations related to it." * * * Symbols of United Nations documents are composed of capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. E/CONF.58/7 UNITED NATIONS PUBLICATION Sales No. E.73.XI.3 Price: $U.S. 5.00 (or equivalent in other currencies) CONTENTS PART ONE Page A. Resolution 1474 (XLVIII) of the Economic and Social Council, convening the Con• ference 3 B. List of representatives and secretariat of the Conference 3 C. Report of the Credentials Committee 12 D. Organization of the Conference and plan of work 13 E. Rules of procedure 15 PART TWO Comparative presentation of the text of the revised draft Protocol on Psychotropic Sub• stances as adopted by the Commission on Narcotic Drugs (January, 1970), and the text of the Convention on Psychotropic Substances adopted by the Conference of Plenipo• tentiaries (February, 1971) 21 PART THREE Record of the work of the Conference leading up to the adoption of the Convention, set out article by article 49 PART FOUR A. Final Act of the United Nations Conference for the adoption of a Protocol on Psycho• tropic Substances 115 B. Convention on Psychotropic Substances, 1971 117 C. Resolutions adopted by the Conference 128 I. Provisional application of the Convention on Psychotropic Substances pending its entry into force 128 II. Research on the amphetamine drugs 129 III. Tribute to the Federal Government of the Republic of Austria 129 D. Draft resolution and draft declaration considered by the Conference 129 E. Complete list of documents of the Conference 130 iii A. RESOLUTION 1474 (XLV1H) OF THE ECONOMIC AND SOCIAL COUNCIL, CONVENING THE CONFERENCE The Economic and Social Council, adopted by the Commission on Narcotic Drugs at its Reiterating its conviction that the problem of the wide• first special session, the report and the summary records spread abuse of psychotropic substances not under inter• of that session, and such background documentation as national control urgently requires to be regulated by he considers pertinent, to all States Members of the international agreement in the form of a treaty, United Nations and members of the specialized agencies or of the International Atomic Energy Agency or parties Recalling its resolutions 1293 (XLIV) and 1294 (XLIV) to the Statute of the International Court of Justice, and of 23 May 1968 and 1401 (XLVI) of 5 June 1969, and also to the World Health Organization, other specialized World Health Assembly resolutions WHA 18.47 of agencies, the International Atomic Energy Agency, the 20 May 1965, WHA 20.42 and WHA 20.43 of 25 May International Narcotics Control Board and to the Inter• 1967 and WHA 21.42 of 23 May 1968, and also General national Criminal Police Organization; Assembly resolution 2433 (XXIII) of 19 December 1968, which refer to this problem, 2. Decides to convene, in accordance with Article 62, Convinced that the objectives and aim of this Protocol paragraph 4, of the Charter of the United Nations and are of interest to the international community as a whole, with the provisions of General Assembly resolution 366 Recalling also its resolution 1402 (XLVI) of 5 June 1969 (IV) of 3 December 1949, a conference of plenipotentiaries in which it had noted the progress made by the Com• for the adoption of the Protocol on Psychotropic Sub• mission on Narcotic Drugs in elaborating a draft Protocol stances ; for the control of the psychotropic substances, and had 3. Requests the Secretary-General: authorized the Commission to meet as early as possible (a) To call such a conference early in 1971; in 1970 to prepare a revised draft Protocol for submission (b) To invite to the Conference: to the Council, (i) The States mentioned in paragraph 1 above; Recalling also that the General Assembly, by resolution 2584 (XXIV) of 15 December 1969, had requested the (ii) The World Health Organization and other Council to call upon the Commission on Narcotic Drugs specialized agencies interested in the matter, at its special session to proceed without delay to complete with the same rights they have at sessions of the the draft Protocol for the control of the psychotropic Economic and Social Council; substances, (iii) The International Narcotics Control Board, Having received the report of the Commission on with the same rights as it has at sessions of the Narcotic Drugs on its first special session,1 Economic and Social Council; Noting that this report contains the text of the revised (iv) The International Criminal Police Organiz• draft Protocol referred to in Council resolution 1402 ation, with the same rights as this organization (XLVI) and General Assembly resolution 2584 (XXIV), has at sessions of the Commission on Narcotic Drugs; 1. Requests the Secretary-General to transmit the (c) To prepare provisional rules of procedure for the revised draft Protocol on Psychotropic Substances conference; 1 Official Records of the Economic and Social Council, Fortyeighth (d) To provide summary records for the Conference Session, Supplement No. 8 (E/4785). and the committees. B. LIST OF REPRESENTATIVES Delegations ALGERIA ARGENTINA Representative: Representative ; M. N. BOULBINA, conseiller juridique au Ministere H.E. Sr. C. A. FERNANDEZ, Embajador Extraordinario des affaires etrangeres, Alger. y Plenipotenciario de Argentina, Viena. Alternate Representative: Alternate Representative: Dr. V. V. OLGUIN, Director de Relaciones Sanitarias M. K. LOKMANE, secretaire d'ambassade, Mission Internacionales, Secretaria de Estado de Salud Publica, permanente de l'Algerie a Geneve. Buenos Aires. Adviser: Adviser: M. S. BouzAR, chef du Service des Stupefiahts, Ministere Dr. E. GRANDE, Director de Fisealizacion Sanitaria, de la sante publique, Alger. Secretaria de Estado de Salud Publica, Buenos Aires. 3 4 The Convention on Psychotropic Substances AUSTRALIA Mr. R. MARSCHIK, Counsellor, Federal Ministry of Representative: Foreign Affairs, Vienna; Mr. E. KUSSBACH, Counsellor, Deputy Legal Adviser of Mr. G. E. SHEEN, Assistant Comptroller-General of the Federal Ministry of Foreign Affairs, Vienna; Customs, Canberra. Mr. W. BREUSTEDT, Deputy Director, Federal Ministry Alternate Representatives: of Finance, Vienna; Dr. A. M. WALSHE, Assistant Director-General, Com• Mr. W. P. PAHR, Head of the International Department, monwealth Department of Health, Canberra; Constitutional Service of the Federal Chancellery, Mr. C. E. MACKENZIE, Assistant Director, Department Vienna; of Customs and Excise, Canberra; Mr. W. SCHWARZ, Deputy Director, Federal Ministry Mr. F. D. POTTS, Chief Pharmaceutical Inspector, of Trade, Vienna; Department of Health Services, Tasmania; Mr. C. MAYERHOFER, Federal Ministry of Justice, Vienna; Mr. A. D. BROWN, First Secretary, Australian Permanent Mr. K. FUCHS, Federal Ministry of Finance, Vienna; Mission to the United Nations, Geneva. Mr. G. KALLINGER, Federal Ministry of Finance, Vienna; Mr. K. ZUSER, Federal Ministry of Trade, Vienna; AUSTRIA Mr. E. HOFFMANN, Federal Police Board, Drugs Branch, Representative: Vienna; Mr. E. NETTEL, Envoy Extraordinary and Minister Mr. P. JANN, Federal Ministry of Justice, Vienna; Plenipotentiary, Federal Ministry of Foreign Affairs, Mr. H. WINKLER, Federal Ministry for Foreign Affairs, Vienna. Vienna. Alternate Representatives: BELGIUM Mr. F. OBERMAYER,
Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Amfepramone (Diethylpropion) Elisa Kit Instructions Product #182119, 182116 & 182113 Forensic Use Only

    Amfepramone (Diethylpropion) Elisa Kit Instructions Product #182119, 182116 & 182113 Forensic Use Only

    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology AMFEPRAMONE (DIETHYLPROPION) ELISA KIT INSTRUCTIONS PRODUCT #182119, 182116 & 182113 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Amfepramone (Diethylpropion) and/or other metabolites in human samples. DESCRIPTION Neogen Corporation’s Amfepramone (Diethylpropion) ELISA (Enzyme-Linked Immunosorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLE The Neogen forensic drug detection ELISA is a solid phase immunoassay designed to detect drugs of abuse for forensic application. The test is performed in microwells coated with a high affinity capture antibody. A control or sample is added to the wells followed by an enzyme conjugate. During the following incubation period, the enzyme conjugate competes with the drug in the sample for binding sites on the antibody coated well. After a wash step to remove any unbound material, substrate is added for the color development process. Acid stop solution is added to discontinue the enzyme-substrate reaction. The color intensity is inversely proportional to the amount of drug present in the sample. Therefore, those samples which contain the drug will inhibit binding of the enzyme conjugate to the capture antibody resulting in less color than the negative control.
  • Partial Agreement in the Social and Public Health Field

    Partial Agreement in the Social and Public Health Field

    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
  • Pharmaceuticals Appendix

    Pharmaceuticals Appendix

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
  • AGENDA Friday, September 9, 2016 7:00 A.M

    AGENDA Friday, September 9, 2016 7:00 A.M

    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.
  • Narcotic Drugs and Psychotropic Substances (Control) Act

    Narcotic Drugs and Psychotropic Substances (Control) Act

    LAWS OF GUYANA Narcotic Drugs and Psychotropic Cap. 35:11 3 Substances (Control) CHAPTER 35:11 NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES (CONTROL) ACT ARRANGEMENT OF SECTIONS PART I PRELIMINARY SECTION 1. Short title. 2. Interpretation. PART II PROHIBITION OF POSSESSION OF AND TRAFFICKING IN NARCOTICS AND CULTIVATION OF CERTAIN PLANTS 3. Definitions for Part II. 4. Penalty for possession of narcotic. 5. Penalty for trafficking in narcotic. 6. Penalty for supply, etc., of narcotic to child or young person if death results from consumption or administration of it. 7. Penalty for bringing into prison or taking out of prison, etc., of a narcotic. 8. Penalty for cultivation of certain plants. 9. Procedure for purposes of section 8(2) to (6). 10. Power of entry in respect of State or Government lands. 11. Power of destruction of prohibited plants. 12. Penalty for certain other acts connected with narcotics. 13. Certain prescriptions to be unlawful. 14. Penalty for receiving additional narcotic or prescription without disclosure of earlier receipt. 15. Removal of name from register. L.R.O. 3/1998 LAWS OF GUYANA 4 Cap. 35:11 Narcotic Drugs and Psychotropic Substances (Control) PART III NARCOTICS IN TRANSIT SECTION 16. Definitions for Part III. 17. Prohibition against sending narcotics by post. 18. Narcotics in transit. 19. Control of Comptroller over narcotics brought into Guyana in transit. 20. Tampering with narcotics in transit. 21. Diversion in Guyana of narcotics in transit. 22. Variations in export authorisation, import authorisation or diversion certificate granted in country other than Guyana. PART IV LICENCES 23. Grant and renewal of licences.
  • Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan

    Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan

    Volume 3 | Number 3 Article 87 2012 Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan Albert I. Wertheimer Follow this and additional works at: http://pubs.lib.umn.edu/innovations Recommended Citation Ninan B, Wertheimer AI. Withdrawing Drugs in the U.S. Versus Other Countries. Inov Pharm. 2012;3(3): Article 87. http://pubs.lib.umn.edu/innovations/vol3/iss3/6 INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing. Commentary POLICY Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan, Pharm.D.1 and Albert I Wertheimer, PhD, MBA2 1Pharmacy Intern, Rite Aid Pharmacies, Philadelphia, PA and 2Temple University School of Pharmacy, Philadelphia PA Key Words: Drug withdrawals, dangerous drugs, UN Banned Drug list Abstract Since 1979, the United Nations has maintained a list of drugs banned from sale in member countries. Interestingly, there are a number of pharmaceuticals on the market in the USA that have been banned elsewhere and similarly, there are some drug products that have been banned in the United States, but remain on the market in other countries. This report provides a look into the policies for banning drug sales internationally and the role of the United Nations in maintaining the master list for companies and countries to use for local decision guidance. Background recently updated issue is the fourteenth issue, which contains At present, one of the leading causes of death in the U.S. is data on 66 new products with updated/new information on believed to be adverse drug reactions.1-14 More than 20 22 existing products.
  • (19) 11 Patent Number: 6165500

    (19) 11 Patent Number: 6165500

    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
  • 2004 Prohibited List

    2004 Prohibited List

    The World Anti-Doping Code THE 2004 PROHIBITED LIST INTERNATIONAL STANDARD (update 17 March 2004) This List shall come into effect on 26 March 2004. THE 2004 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 26 March 2004 (Updated 17 March 2004) SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES S1. STIMULANTS The following stimulants are prohibited, including both their optical (D- and L-) isomers where relevant: Adrafinil, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, bromantan, carphedon, cathine*, clobenzorex, cocaine, dimethylamphetamine, ephedrine**, etilamphetamine, etilefrine, fencamfamin, fenetylline, fenfluramine, fenproporex, furfenorex, mefenorex, mephentermine, mesocarb, methamphetamine, methylamphetamine, methylenedioxyamphetamine, methylenedioxymethamphetamine, methylephedrine**, methylphenidate, modafinil, nikethamide, norfenfluramine, parahydroxyamphetamine, pemoline, phendimetrazine, phenmetrazine, phentermine, prolintane, selegiline, strychnine, and other substances with similar chemical structure or similar pharmacological effect(s)***. * Cathine is prohibited when its concentration in urine is greater than 5 micrograms per millilitre. ** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per millilitre. *** The substances included in the 2004 Monitoring Program are not considered as Prohibited Substances. The Prohibited List 2004 1 26 March 2004 S2. NARCOTICS The following narcotics are prohibited: buprenorphine, dextromoramide,
  • Video Course Evaluation Form My Name Is

    Video Course Evaluation Form My Name Is

    Garden State CLE 2000 Hamilton Avenue Hamilton, New Jersey 08619 (609) 584-1924 – Phone (609) 584-1920 - Fax Video Course Evaluation Form My Name is: __________________________________________ Name of Course: ______________________________________ My Street address: _____________________________________ City: _____________________ State: _____ Zip Code: ____ Email Address: ________________________________________ Please Circle the Appropriate Answer Instructors: Poor Satisfactory Good Excellent Materials: Poor Satisfactory Good Excellent CLE Rating: Poor Satisfactory Good Excellent Required: Secret words that appeared on the screen during the seminar. 1) __________________________ 2) _______________________ 3) __________________________ 4) _______________________ What did you like most about the seminar? _____________________________________________________________ _____________________________________________________________ What criticisms, if any, do you have? _____________________________________________________________ _____________________________________________________________ I certify that I watched, in its entirety, the above-listed CLE Course. Signature ___________________________________ Date_________ In order to receive your CLE credits, please send our payment and this completed form to Garden State CLE, 2000 Hamilton Avenue, Hamilton, New Jersey, 08619. BURLINGTON COUNTY BAR ASSOCIATION --- Interpreting Your Client’s Drug Lab Results: Were They Impaired? © Chris Baxter 2020 DO LAB RESULTS MATTER IN A DUI-D? YES ➢State